Flurbiprofen
to Prevent Intraoperative Miosis During Cataract IOL Surgery
Sawang
Ponglertnapakorn M.D.,
Prut Hanutsaha M.D.,
Skowrat Kunavisarut M.D.,
Tiam Lawtiantong M.D.,
Department of Ophthalmology,
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
ABSTRACT During
October 1989 to April 1990, seventy one patients were enrolled in a randomized,
double blind controlled trial to study the efficacy of flurbiprofen in preventing
intraoperative miosis during cataract IOL surgery.
The
patients were divided into 4 groups, 3 patients received 1 % tropicamide alone,
23 patients received 1% tropicamide and 10% phenylephrine, 7 patients received
1% tropicamide and 0.03% flurbiprofen, and 38 patients received 1% tropicamide
and 10% phenylephrine and 0.03% flurbiprofen.
The mean changes of the
pupillary diameter after conjunctival incision and after IOL insertion in
each group were 0.26, 1.30, 0.58 and 0.72 mm respectively. The mean
decrease of pupillary diameter in flurbiprofen treated group (group 4) was
lesser than that of the non flurbiprofen treated group (group 2) with statistically
significant (p=0.002). There was no difference in the effect of flurbiprofen
in diabetic and non-diabetic patients. Therefore, we concluded that flurbiprofen
have clinical role in preventing miosis during cataract IOL surgery in diabetic
and non diabetic patients.
|